NCT07506356Recruiting
Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors
Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors Agonists
Source: ClinicalTrials.gov · Last updated 1 Apr 2026
Brief summary (registry, in English)
Treatment with semaglutide slows down gastric emptying , food remains in the stomach for a longer period of time. This slowing has important implications for anesthesia management. At present, we do not know the optimal duration for discontinuing this medication before surgery and anesthesia to ensure an empty stomach. This is an observational research project, conducted exclusively at the Geneva University Hospitals (HUG). To answer the research question, participation of 38 individuals will be required. The duration of participation for each person is 7 days. To recruit the necessary number of participants, approximately 1.5 years will be needed. This project is being carried out in accordance with Swiss legal requirements and recognized international guidelines. The competent ethics committee has reviewed and approved this project. The project will last 7 day during which the participants will need to come 3 times at the hospital to make gastric ultrasounds. On these days the participants will be asked to have a breakfast between 7 and 8 am including a minimum of bread and/or cereals and/or proteins. After that the participants will be asked to fast for 6 hours for solide food and 2 hours for liquids. If the participants smokes, they must for 12h before the exam. At 2Pm an anesthesiologist will welcome the participant to make the exam at the hospital to evaluate the gastric volume after what the participants will be able to get a small collation and go back home.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 38 (estimated)
- First submitted
- 21 Mar 2026
- Start date
- Apr 2026
- Primary completion date
- Dec 2026
- Lead sponsor
- University Hospital, Geneva
- Diseases
- Type 2 diabetes
- NCT number
- NCT07506356
What you commit to
- Study type: Observational
- Planned participants: 38
- From Apr 2026 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Past gastric surgery
Other illness
- Gastro intestinal motility disorders
- Inability to follow the instructions for the exam (language, dementia)
Other
- Insuline treatment
- Hiatal hernia
- Recent trauma
- Inability to be lay down for the exam
- BMI \> 40
- Inability to stop smoking 12h before the measures
Who the study is looking for
- Female/ Male of 18 years old or more
- With Type 2 Diabetes
- Treated with GLP 1 analog for more than 3 months
- Signed consent
- ASA between I and IV
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hôpitaux universitaires de Genève Coordinator of this site? Confirm its status | Geneva | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.